Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables (2020 - 2025)

Historic Receivables for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • Caribou Biosciences' Receivables rose 1087.31% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 1087.31%. This contributed to the annual value of $2.1 million for FY2024, which is 1400.99% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Receivables is $2.1 million, which was up 1087.31% from $2.0 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Receivables high stood at $7.6 million for Q2 2021, and its period low was $1.9 million during Q3 2024.
  • For the 5-year period, Caribou Biosciences' Receivables averaged around $3.3 million, with its median value being $2.5 million (2022).
  • As far as peak fluctuations go, Caribou Biosciences' Receivables surged by 7317.33% in 2021, and later tumbled by 6309.52% in 2022.
  • Caribou Biosciences' Receivables (Quarter) stood at $6.6 million in 2021, then tumbled by 63.1% to $2.4 million in 2022, then fell by 0.61% to $2.4 million in 2023, then decreased by 14.01% to $2.1 million in 2024, then fell by 1.1% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.0 million for Q2 2025, and $1.9 million during Q1 2025.